Hanson Wade’s Post

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

We recently hosted a session at Nordic Life Science Days 2024, where industry leaders gathered to discuss the challenges and opportunities in advancing patient centricity within the pharmaceutical sector.   Despite the ongoing efforts across the industry to address patient needs throughout drug discovery, development, and commercialization, significant gaps remain. These challenges include identifying unmet needs early on, navigating increasingly complex clinical trials, and ensuring product availability.   Dr. Ulrica Sehlstedt, Arthur D. Little’s Global Leader for the Healthcare & Life Sciences practice, moderated a panel featuring Christophe Bourdon, CEO of LEO Pharma; Kati Kaijasilta, Business Development Director at Orion Pharma Ltd; Mike Ryan, General Manager Europe at EVERSANA; and Dr. Holger Kissel, Senior Vice President Scientific Relations and Liaison at BioNTech SE. Together, they explored how leading pharmaceutical companies are working to overcome these challenges to enhance patient value and achieve commercial success.   The discussions were insightful, and while we are encouraged by the innovative progress being made, it is clear there is still much work ahead. We look forward to continuing to collaborate across the industry to drive further improvements for patients.   #NLSDays #HealthcareInnovation #PatientCentricity

What began as a deep dive into the Nordic pharmaceutical market, in partnership with Enterprise Ireland Nordics, led to valuable conversations with decision-makers from Novo Nordisk, AstraZeneca, Lundbeck, Novartis, and LEO Pharma. During a webinar in Copenhagen, and through this week’s released report to Irish businesses, I highlighted over $22.88 billion USD in strategic investments across the top 10 Pharma companies in Denmark and Sweden. Consider this as a spark for curiosity—see how these figures reveal the Nordic region’s bold drive to lead the future of healthcare, from advanced therapies to digital health and sustainability. So far, the focus has been on understanding what I call the 'Pipeline to Production' chain, identifying where strategic investments in the past 2-3 years matter most, and connecting with the minds driving progress. Here’s a sneak peek of insights from conversations with industry leaders—and a special thanks to Michael Norman for the great collaboration and support—his insights were invaluable in shaping our approach.

Mega proud to be part of this wonderful initiative. If you are involved in a partnership between biopharmaceutical companies and patient organisations, there is still time to register to take part via the link below!! Partnerships can be in any of the following: 💗Communications 📢 Advocacy 🌐Market Access 🔬Clinical trials 🧪R&D #patientadvocacy #marketaccess #healthcarecommunications

On the cross-country flight home from a wonderful and busy BIO International Convention, I spent some time reflecting on three years here at the National Pharmaceutical Council. I still remember flying to DC as the brand-new President and CEO of the organization in June 2021 – a trip that simultaneously feels like yesterday and a lifetime ago, given the changes in the industry, health policy, and research environment. The work of NPC has never been more relevant — or more important. We have a great team, and this team appreciates the challenges we face. Here are three reflections I’d offer for anyone interested in the future of innovation. • To meet the challenges of today and tomorrow, NPC has built new capabilities that allow us to build on our 70-year legacy as we conduct rigorous, policy-relevant research and communicate it with impact. I invite you to learn more about the value we provide to NPC members and the benefits member companies experience. https://lnkd.in/etCWVqTE • NPC’s research informs many of the important policy conversations going on right now. To stay up to date on our latest, I hope you subscribe to the NPC This Week Newsletter to get a weekly look-ahead at the policy, research, and industry conversations that matter to the future of biopharmaceutical innovation. https://lnkd.in/eBAj7B_B  • I’m proud of the team at NPC and what we’ve accomplished — while recognizing the challenges in front of us. If you’d like to see more of our recent research, analysis, and work, check out our 2023 Annual Report. https://lnkd.in/eB6u2nWd  I’ve loved every minute of the past three years and look forward to many more. These aren’t challenges we can solve alone, and it has never been more important for drugmakers, payers, and policymakers to understand the ecosystem and work together for the benefit of patients. If we haven’t spoken in a while, I’d love to hear from you, whether in the DMs, email, or phone.  #pharma #innovation #healthpolicy

Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments.   It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) – the main body representing the research-based biopharmaceutical industry in Europe.   Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIA’s mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 – but as EFPIA’s mission alludes, this is only possible with the right policy and legislative environment in place.   Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd   #EFPIA #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess  

Looking at the 20 top pharma companies by market cap reveals some clear trends, yet others are more subtle: #Medicalscienceliaison #MedicalAffairs #PharamceuticalIndustry While Eli Lilly and Novo Nordisk have long been in the top 20, only in the last ~2 years have they broken into the top tier, thanks to their GLP-1s. Lilly is now amongst the 10 most valuable companies in the world, across all industries. While weight loss drugs have gotten the headlines, others delivered impressive gains over the last 3 years as well: AstraZeneca increased its value by ~50%, largely thanks to its strong oncology portfolio, with blockbusters like Tagrisso that delivered ~$6B in sales in FY2023. Meanwhile, Regeneron and Vertex almost doubled their value, driven by Dupixent/Eylea and Trikafta respectively. One of the most surprising results is from AbbVie, which increased its market cap from ~$200B to ~$300B in the last 3 years, despite the fact its best-seller Humira began to face competition during that time. 👩⚕️ 💊 Have you joined the MSL and medical affairs linkedin community yet? Over 18.000 med. affairs professionals across the globe sharing jobs, tips and actively networking.   🛎 👉 This is the link: https://lnkd.in/gZ_mBprH

LET’S CONNECT ▸ This March, Akesa joins industry leaders, innovators, and professionals from across the globe in conversations that will help shape the future of clinical trials. We’ll be travelling across Europe and Asia and are excited to connect at: 🌍 CLINICAL TRIAL SUPPLY EUROPE 2024 - 6-7 March: Kicking off in Barcelona, we look forward to connecting with peers to explore the latest in clinical trial supplies and logistics solutions. 🌍 BIO-EUROPE SPRING - 18-20 March: Next, we head to BIO-Europe Spring in Barcelona, where the focus will be on fostering collaborations that drive the pharmaceutical and biotech industry forward. 🌍 IMAPAC CLINICAL TRIALS FESTIVAL 2024 - 20-21 March: Almost concurrently, we'll be part of the IMAPAC Clinical Trials Festival in Singapore, engaging in discussions on innovative trial designs and patient-centric strategies. Though the Australian Biologics Festival 2024 (20-21 February) has passed, our experiences there have only fuelled our enthusiasm for the insights and partnerships these upcoming events promise. Whether you’re interested in discussing the future of clinical trials, exploring collaborations, or simply sharing insights, Con Konstantopoulos, George Vlachos, Karen Montgomery-Douglas and Julian Battistella are eager to connect at these conferences to shape the future of clinical trials together. #Akesa #ClinicalTrials #PharmaceuticalIndustry #Biologics #Networking #Conference

The end is fast approaching! Just 1 day to go until registrations close for the Patient Partnership Index 2023.    If you would like to showcase your involvement in a partnership between biopharmaceutical companies and patient organisations across communications, advocacy, market access, clinical trials, or R&D, register now to submit an entry.     Entries can be led by either partner and will be judged against a bespoke metric developed in partnership with industry and patient organisations to award Gold, Silver or Finalist standards.    Entries to the Index close at 23:55 on Friday 26th April, so register now to receive an entry form, and ensure your partnerships get the recognition they deserve.     The registration form, alongside FAQs and insights from last year’s Index, can be found via the link in comments.    If you have any questions or require further support to get your entry (or entries) in by Friday, please reach out to the PPI team at info@patientpartnershipindex.co.uk.     #clinicaltrials #marketaccess #researchanddevelopment #patientadvocacy #healthcarecommunications 

Based at our ARC Uxbridge campus, Amgen has achieved a significant milestone by securing the first-ever approval via the new International Recognition Procedure (IRP). This breakthrough will expedite the availability of life-saving medicines to UK patients, ensuring quicker access to innovative treatments. We're thrilled to announce that XGEVA (denosumab), a critical treatment for preventing serious bone-related complications and treating giant cell tumors of bone, is the first product authorized under this new procedure by the MHRA. The IRP leverages global regulatory expertise, streamlining the approval process and benefiting patients sooner. Julian Beach, MHRA Interim Executive Director, emphasised the importance of rapid access to safe and effective treatments, highlighting that the IRP granted this first approval in just 30 days. Health Minister Andrew Stephenson also expressed enthusiasm for this international collaboration, which reduces bureaucracy and accelerates patient access to new medicines. Read the full release here: https://lnkd.in/e7Xz9Ukp ARC Uxbridge continues to thrive with a dynamic biotech and pharmaceutical cluster, including industry leaders like Bristol Myers Squibb, Parexel, and Daiichi Sankyo Europe GmbH. #HealthcareInnovation #LifeSciences #Biotech #ARCuxbridge #PatientCare #innovation Amgen